Thymulin: A Review of Medical Evidence and Therapeutic Potential

Authors: Monis, A. and Maple, K.

Date: November 2024

Abstract

Thymulin, a peptide hormone originating in the thymus, is integral to immune system regulation and neuroendocrine functions. Traditionally linked to thymus-driven immunity, recent research highlights a broader therapeutic potential for thymulin, especially in inflammation control and hormonal modulation.

Compelling evidence underscores thymulin's anti-inflammatory properties, demonstrated in experimental models of inflammation, pulmonary hypertension, and type 1 diabetes. Additionally, thymulin's effects extend to key intracellular pathways, such as p38 MAPK and NF-kB, both essential for regulating immune and inflammatory responses.

This white paper aims to present key findings on the clinical implications of thymulin and explore its potential for wider medical applications. By synthesizing current evidence, this overview seeks to deepen understanding of thymulin's therapeutic role and highlight the importance of further research to clarify its long-term impact and the mechanisms that drive its effects.

Table of Contents

Introduction

Thymulin is a nonapeptide hormone, composed of nine amino acids, secreted by epithelial cells in the thymus. This hormone, essential for immune health, functions as an immunomodulator and relies on the presence of zinc for its biological activity. As the primary organ for immune cell production and maturation, the thymus plays a crucial role in defending the body against foreign antigens, with thymulin being central to this process.

Initially known as *facteur thymique serique* (FTS), thymulin was first isolated from porcine serum and later purified from human serum. By 1977, researchers had determined its amino acid sequence—Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH—and successfully synthesized the peptide, confirming its full biological activity. Thymulin consists of a biologically inactive nonapeptide component that becomes active when coupled with zinc ions in a 1:1 ratio, which is essential for its immunoregulatory function.

In addition to its established role in immune system regulation, thymulin is being actively explored for its anti-inflammatory properties and other therapeutic applications, making it a focus of ongoing research in immune and inflammation-related therapies.

Problem Statement

Thymulin's role in immune regulation and overall health is well-established, with studies showing that its concentration and activity are influenced by factors like age and zinc levels. Disruptions in thymulin can weaken immune defenses, potentially leading to various health issues, including chronic inflammation and immune dysfunction. As a result, thymulin has garnered increasing interest as researchers explore its therapeutic potential.

Despite decades of research, much remains to be discovered about thymulin's specific mechanisms, broader applications, and potential clinical benefits. Understanding these aspects could unlock new avenues for its use in managing immune-related disorders and enhancing overall health. Thymulin's promising role continues to make it a focus of research as scientists work to unravel its complex functions and assess its viability in therapeutic applications.

Literature Review

This white paper synthesizes findings from researchers including B. Nasseri, M. Santos, S.M. Lunin, E.G. Novoselova, and P.C. Reggiani, providing a comprehensive analysis of thymulin's medical relevance and potential therapeutic applications. It also incorporates research by T. Henriques-Coelho, M. Dardenne, C. Meazza, and H. Folch, who investigated thymulin's anti-inflammatory effects, neuroprotective roles, and impact on immune response regulation.

Additionally, studies by S. Wade offer valuable insights into thymulin activity in specific populations, such as patients with anorexia nervosa, while B. Safieh-Garabedian's team explored thymulin analogs as potential treatments for neurodegenerative conditions.

Together, this body of evidence illuminates thymulin's interactions with crucial pathways like p38 MAPK and NF-kB, its role in reducing chronic inflammation, and its modulation of hormonal release and stress responses. Beyond thymulin's foundational functions, this white paper examines its potential applications in managing conditions such as type 1 diabetes, chronic sepsis, and pulmonary hypertension. Collectively, these studies underscore thymulin's promise as a versatile therapeutic agent, highlighting the need for further research to deepen our understanding of its mechanisms and therapeutic potential.

Methodology

The primary objective of this white paper is to provide an in-depth analysis of the therapeutic and physiological effects of thymulin across various applications. This document draws on a range of studies highlighting thymulin's anti-inflammatory properties and its essential role in immune regulation. Additionally, it evaluates potential therapeutic uses for thymulin in managing conditions such as type 1 diabetes, chronic inflammation, neurological disorders, and pulmonary hypertension.

Beyond its primary effects, this white paper explores thymulin's impact on key signaling pathways involved in inflammatory responses, as well as its interactions with immune cells and cytokine production. The scope of the paper includes experimental research using animal models, in vitro studies, and comprehensive reviews that assess thymulin's efficacy in modulating immune responses, hormonal secretion, and oxidative stress responses. This broad analysis seeks to uncover the diverse potential of thymulin in medical applications and to investigate its underlying mechanisms of action.

Moreover, this paper considers the viability of thymulin as a co-therapeutic agent, presenting findings that outline both its benefits and limitations. Ultimately, this white paper aims to advance understanding of thymulin's multifaceted role in health and therapeutic contexts, underscoring the need for further exploration and clinical investigation.

Results/Findings

In their study of thymulin's effects on inflammatory responses, **B. Nasseri et al.** examined how different doses and timings of intraperitoneal thymulin administration affected spinal microglial activity in an inflammatory rat model. Using Complete Freund's Adjuvant (CFA) to induce inflammation, the researchers administered thymulin for 21 days. Their findings were promising: thymulin significantly reduced thermal hyperalgesia and paw edema, alleviating the pain and swelling caused by CFA. The team noted that thymulin inhibited the activation of microglia, decreased phosphorylation of p38 MAPK, and reduced pro-inflammatory cytokine production in the spinal cord, suggesting that thymulin's anti-inflammatory effects are largely mediated through its suppression of spinal microglia and other central inflammatory mediators.

In a review focused on thymulin's role in lung disease, **M. Santos et al.** highlighted its anti-inflammatory potential. Their analysis revealed that thymulin selectively boosts anti-inflammatory cytokines while suppressing pro-inflammatory ones. Thymulin also inhibits p38, which is involved in glucocorticoid resistance, and NF-kB activation, a pathway known to contribute to several lung diseases. Given thymulin's extensive anti-inflammatory effects in animal models, Santos and colleagues call for further research to explore its applications in treating lung conditions.

S.M. Lunin et al. hypothesized that thymulin might be produced by cells outside the thymus during stress. Their research confirmed this, finding that both macrophages and fibroblasts can secrete thymulin. Interestingly, while both cell types released similar amounts, macrophages showed a heightened response to stress. The team suggested that thymulin may be derived from a 60 kDa protein found in macrophages, which splits to form a thymulin-like compound during oxidative stress. This discovery offers new insights into thymulin's roles beyond immune modulation, connecting it to broader neuroendocrine and intracellular responses to stress.

In exploring thymulin's potential for treating diabetes, **E.G. Novoselova et al.** compared thymulin and peroxiredoxin 6 (PRDX6) in a type 1 diabetes mouse model. Both compounds improved inflammation and immune responses, but thymulin uniquely regulated the JNK pathway, critical for controlling immune responses, specifically normalizing JNK activity in diabetic mice's spleen cells. Thymulin also increased insulin-positive areas in the pancreas, making it a compelling candidate for diabetes management.

P.C. Reggiani et al. delved into thymulin's regulatory role on the thymulin-pituitary axis, examining its impact on hormone release, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH). They reviewed research showing thymulin's influence on pituitary hormone release and cyclic nucleotide formation. Their findings also indicated that thymulin's effects on hormone release decrease with age, suggesting that aging reduces pituitary sensitivity to thymulin. Notably, gene therapy with thymulin in newborn mice restored LH and FSH levels and prevented ovarian dysgenesis, highlighting its potential in reproductive health.

M. Dardenne et al. examined thymulin's potential as an anti-inflammatory and analgesic agent. They observed that thymulin injections helped alleviate inflammatory pain through a neuroimmune loop involving prostaglandin-E2 and capsaicin-sensitive nerve fibers. By reducing cytokine levels in specific brain regions, thymulin demonstrated a neuroprotective effect on the central nervous system, making it a promising agent for managing inflammatory pain.

In immunohistological studies, **H. Folch et al.** found that thymulin stains various thymic structures, including reticular cells and Hassall's corpuscles. This thymulin-positive cell population, found throughout the thymus and peripheral immune tissues, suggests that thymulin-producing cells may contribute to immune responses across the lifespan.

E.G. Novoselova et al. extended their research on thymulin to chronic septic inflammation, where thymulin lowered fever, reduced apoptosis, and improved serotonin and melatonin levels in mice. This protective effect suggests that thymulin could be valuable as a co-therapeutic agent in sepsis, possibly working through the NF-kB pathway, which it suppresses. Novoselova's team proposed that thymulin might act as a damage-associated molecular pattern (DAMP)-like molecule, produced by stressed cells to mediate immune responses.

In pulmonary hypertension research, **T. Henriques-Coelho et al.** discovered that thymulin administration in a rat model prevented pulmonary hypertension's morphological and hemodynamic changes, most likely by suppressing the p38 pathway. Their results indicate that thymulin could play a role in treating this serious condition.

C. Meazza et al. studied the interplay of thymulin, zinc, and growth hormone in newborns, finding that thymulin levels increased significantly in newborns compared to their mothers. They observed that thymulin, zinc, and growth hormone levels correlated with CD4 and CD antigen markers, suggesting that thymulin may be involved in immune development and growth regulation early in life.

Investigating thymulin in anorexia nervosa patients, **S. Wade et al.** found that decreased thymulin activity was associated with thymic atrophy due to malnutrition and hormonal imbalances. Reduced thymulin levels may contribute to immune response variability in these patients, particularly when weight loss is severe.

In a study of thymulin's role in the somatotropic axis, **P.C. Reggiani et al.** observed that thymulin immunoneutralization in mice resulted in increased growth hormone levels and somatotrope cell size. The results underscore thymulin's involvement in regulating body growth and hormone secretion, particularly in the thymus-somatotropic axis.

Lastly, **B. Safieh-Garabedian et al.** explored a thymulin analog's effects in neurodegenerative conditions. Their study found that the peptide reduced brain inflammation and provided analgesic effects, indicating potential applications in treating neurodegeneration related to chronic inflammation.

Together, these studies paint a compelling picture of thymulin as a versatile therapeutic agent. From immune modulation to neuroprotection and growth regulation, thymulin's extensive influence across biological systems supports its potential as a promising compound for diverse medical applications.

Discussion

The extensive research examined in this white paper illustrates thymulin's potential as a highly versatile therapeutic agent, with findings that underscore its impressive immunomodulatory, anti-inflammatory, and neuroprotective effects. Thymulin is uniquely positioned to address today's pressing health concerns related to inflammation and immune dysregulation, as research highlights its powerful influence on immune responses, inflammation reduction, and hormonal balance. For example, B. Nasseri et al. showed thymulin's ability to alleviate pain and inflammation in animal models, while Novoselova and her team demonstrated its role in diabetes management through the JNK pathway, indicating thymulin's therapeutic promise in conditions ranging from metabolic disorders to chronic inflammatory diseases.

While many studies have been conducted on animal models, these results are both compelling and encouraging. The range of benefits reported—targeting multiple conditions—presents thymulin as a valuable addition to any therapeutic protocol for immune-related or inflammatory conditions. In addition, extensive research evidence, such as the work of M. Santos and E.G. Novoselova, supports thymulin's anti-inflammatory effects on key signaling pathways like p38 MAPK and NF-kB. The work of S.M. Lunin further explored thymulin's role in stress response, illustrating the complex ways thymulin helps regulate the immune system.

Overall, these findings indicate that thymulin could become a valuable asset in treating chronic inflammation and immune dysregulation. As evidence continues to mount, the therapeutic benefits of thymulin stand out, even though most research is based on preclinical studies. More complex, human-based studies would provide further validation, but the current data underscores its potential as a safe, effective solution to modern health challenges.

Conclusion

Thymulin offers a revolutionary approach to enhancing health by targeting the root causes of inflammation, immune dysfunction, and hormonal imbalance. Its potential applications are vast: research suggests that thymulin can strengthen immune function, support neurological health, and even improve metabolic balance. The benefits of thymulin make it a valuable addition for anyone looking to address immune-related health issues, reduce chronic inflammation, or support overall health and vitality.

While most research to date is based on animal studies, the consistent findings from multiple researchers point to a transformative product that could provide substantial therapeutic benefits. With more human trials, thymulin's full potential as a modern medical treatment could be realized. This powerful compound presents a valuable opportunity to support health across multiple domains, making it an essential consideration for managing today's diverse health conditions effectively.

Embrace thymulin therapy to harness its potential and unlock a healthier future, supported by a strong foundation of research and promising evidence.

References

Nasseri B, Zaringhalam J, Daniali S, Manaheji H, Abbasnejad Z, Nazemian V. Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signaling pathways. *Int Immunopharmacol*. 2019;70:225-234. doi:10.1016/j.intimp.2019.02.042

Santos M, Henriques-Coelho T, Leite-Moreira A. Immunomodulatory role of thymulin in lung diseases. *Expert Opin Ther Targets*. 2010;14(2):131-141. doi:10.1517/14728220903512991

Lunin SM, Khrenov MO, Glushkova OV, et al. Extrathymic production of thymulin induced by oxidative stress, heat shock, apoptosis, or necrosis. *Int J Immunopathol Pharmacol*. 2017;30(1):58-69. doi:10.1177/0394632017694625

Novoselova EG, Glushkova OV, Lunin SM, et al. Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice. *Int J Immunopathol Pharmacol*. 2021;35:20587384211005645. doi:10.1177/20587384211005645

Reggiani PC, Poch B, Cónsole GM, et al. Thymulin-based gene therapy and pituitary function in animal models of aging. *Neuroimmunomodulation*. 2011;18(5):350-356. doi:10.1159/000329495

Zaidi SA, Kendall MD, Gillham B, Jones MT. The release of luteinizing hormone from pituitaries perifused with thymic extracts. *Thymus*. 1988;12(4):253-264.

Hadley AJ, Rantle CM, Buckingham JC. Thymulin stimulates corticotrophin release and cyclic nucleotide formation in the rat anterior pituitary gland. *Neuroimmunomodulation*. 1997;4(2):62-69. doi:10.1159/000097322

Hinojosa L, García L, Domínguez R, et al. Effects of thymulin and GnRH on the release of gonadotropins by in vitro pituitary cells obtained from rats in each day of estrous cycle. *Life Sci*. 2004;76(7):795-804. doi:10.1016/j.lfs.2004.07.017

Dardenne M, Saade N, Safieh-Garabedian B. Role of thymulin or its analogue as a new analgesic molecule. *Ann N Y Acad Sci*. 2006;1088:153-163. doi:10.1196/annals.1366.006

Folch H, Villegas JV, Leyan V, Barría M, Eller G, Esquivel P. Immunohistochemical evidences showing the presence of thymulin containing cells located in involuted thymus and in peripheral lymphoid organs. *Biol Res*. 2010;43(3):291-298.

Novoselova EG, Lunin SM, Glushkova OV, et al. Thymulin, free or bound to PBCA nanoparticles, protects mice against chronic septic inflammation. *PLoS One*. 2018;13(5):e0197601. Published 2018 May 24. doi:10.1371/journal.pone.0197601

Henriques-Coelho T, Oliveira SM, Moura RS, et al. Thymulin inhibits monocrotaline-induced pulmonary hypertension modulating interleukin-6 expression and suppressing p38 pathway. *Endocrinology*. 2008;149(9):4367-4373. doi:10.1210/en.2008-0018

Meazza C, Mocchegiani E, Pagani S, Travaglino P, Bozzola M. Relationship between thymulin and growth hormone secretion in healthy human neonates. *Am J Perinatol*. 2007;24(4):227-233. doi:10.1055/s-2007-972924

Wade S, Bleiberg F, Mossé A, et al. Thymulin (Zn-facteur thymique serique) activity in anorexia nervosa patients. *Am J Clin Nutr*. 1985;42(2):275-280. doi:10.1093/ajcn/42.2.275

Reggiani PC, Martines EV, Camihort GA, Poch B, Goya RG, Cónsole GM. Role of thymulin on the somatotropic axis in vivo. *Life Sci*. 2012;91(5-6):166-171. doi:10.1016/j.lfs.2012.06.037

Lunin SM, Khrenov MO, Novoselova TV, Parfenyuk SB, Novoselova EG. Thymulin, a thymic peptide, prevents the overproduction of pro-inflammatory cytokines and heat shock protein Hsp70 in inflammation-bearing mice. *Immunol Invest*. 2008;37(8):858-870. doi:10.1080/08820130802447629

Safieh-Garabedian B, Jabbur SJ, Dardenne M, Saadé NE. Thymulin related peptide attenuates inflammation in the brain induced by intracerebroventricular endotoxin injection. *Neuropharmacology*. 2011;60(2-3):496-504. doi:10.1016/j.neuropharm.2010.11.004

Appendices



Protein bands at regions corresponding to 60 kDa and 10 kDa that are stained by thymulin antibody.

Lunin SM, Khrenov MO, Glushkova OV, et al. Extrathymic production of thymulin induced by oxidative stress, heat shock, apoptosis, or necrosis. *Int J Immunopathol Pharmacol*. 2017;30(1):58-69. doi:10.1177/0394632017694625



Effects of thymulin and PRDX6 on the activity of JNK pathway and NF-kB.

Novoselova EG, Glushkova OV, Lunin SM, et al. Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice. *Int J Immunopathol Pharmacol*. 2021;35:20587384211005645. doi:10.1177/20587384211005645

Acknowledgments

The authors of this white paper acknowledge Nasseri B, Santos M, Lunin S.M, Novoselova E.G, Reggiani P.C, Zaidi S.A, Hadley A.J, Hinojosa L, Dardenne M, Folch H, Henriques-Coelho T, Meazza C, Wade S, and Safieh-Garabedian B for their meaningful contributions to previous research, experiments, clinical trials, and reviews. Their findings and discoveries have been crucial for understanding thymulin and its potential uses and clinical applications. It is thanks to their findings that we were able to make important conclusions in this white paper.

Conflicts of Interest

The authors had no conflicts of interest to declare at the time of writing this white paper.

Contact Information

Should you have any inquiries regarding this white paper, please contact the authors directly.